wild/抗癌药

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to methods and nucleic acid vector compositions for modifying gene expressing, involving the preparation and use of improved retroviral vectors which encode antisense RNA molecules or, alternatively,

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates generally to the area of recombinant technology. In some aspects, it concerns simplified and efficient methods of generating recombinant adenovirus. In other aspects, novel compositions and methods involving p53

This application is the U.S. National Phase under 35 U.S.C. .sctn.371 of International Application PCT Patent Application No. PCT/KR2004/001941, filed on Aug. 2, 2004, which claims priority to Korean Patent Application No. 10-2004-055088, filed on Jul. 15, 2004, the contents of which are all herein

FIELD OF THE INVENTION This invention relates to obtaining purified bindweed and buckwheat extracts by collecting components of a homogenized aqueous solution of bindweed material. High molecular weight extracts of bindweed were previously shown to inhibit the growth of two different types of

FIELD OF THE INVENTION This invention relates to obtaining purified bindweed and buckwheat extracts by collecting components of a homogenized aqueous solution of bindweed material. High molecular weight extracts of bindweed were previously shown to inhibit the growth of two different types of

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a U.S. national phase of International Application No. PCT/KR2009/006523 filed on Nov. 6, 2009, which claims the benefit of Korean Application No. 10-2008-0110086 filed on Nov. 6, 2008, the contents of which are hereby incorporated by

TECHNICAL FIELD The present invention relates to a cancer cell proliferation inhibitor that is capable of inhibiting proliferation of at least one of a cancer cell overexpressing a wild-type epidermal growth factor receptor and a cancer cell expressing an epidermal growth factor receptor mutant

FIELD OF THE INVENTION The present invention is directed to defective Sindbis viral vectors, plasmids used to produce such vectors, pharmaceutical formulations containing the vectors, and methods for their production and use to treat mammals suffering from tumors. BACKGROUND OF THE INVENTION Sindbis

This is a National Phase Application filed under 35 U.S.C. 371 as a national stage of PCT/EC2008/000007, filed on Sep. 18, 2008, an application claiming the benefit under 35 U.S.C. 119 of Ecuadorian Application No. SP07-7765, filed on Sep. 21, 2007, the content of each of which is hereby

The present invention provides viral agents that have application in the treatment of neoplasms such as tumours, particularly tumours derived from colon cells, more particularly liver tumours that are metastases of colon cell primary tumours. Still more particularly are provided replication

The present invention provides viral agents that have application in the treatment of neoplasms such as tumours, particularly tumours derived from colon cells, more particularly liver tumours that are metastases of colon cell primary tumours. Still more particularly are provided replication

TECHNICAL FIELD The present invention relates to methods of treating mammals, for example humans, by administering a superantigen and an anticancer agent. More particularly, the invention relates to the administration of a superantigen and an anticancer agent for the treatment of a

TECHNICAL FIELD The present invention relates to methods of treating mammals, for example humans, by administering a superantigen and an anticancer agent. More particularly, the invention relates to the administration of a superantigen and an anticancer agent for the treatment of a

REFERENCE TO SEQUENCE LISTING, TABLE OR COMPUTER PROGRAM The Sequence Listing is concurrently submitted herewith the specification as an ASCII formatted text file via EFS-Web with a file name of Sequence Listing.txt with a creation date of Dec. 12, 2012, and a size of 3 kilobytes. The Sequence

The present invention provides new chemical entities, particularly steroidal C-17 benzoazoles, pyrimidinoazoles (azabenzoazoles) and diazines. It is also provides methods for the synthesis of the benzoazoles, pyrimidinoazoles and diazines. In one embodiment, the methods for synthesizing benzoazoles